Research
Hormonal
Dual activation of GPR10 and NPFF2 receptors by lipidated PrRP31 metabolites produces robust, long-acting weight loss in diet-induced obese mice, whereas GPR10-selective activation does not.
This research suggests that for obesity treatment, targeting both GPR10 and NPFF2 receptors simultaneously may be more effective than targeting GPR10 alone. The study used lipidated peptides in mice, showing significant weight loss. This is preclinical data and not a direct human treatment recommendation yet.
ModerateSupportsMEDIUM confidence
Combined GPR10 and NPFF2R activation may therefore be a critical mechanism for obtaining robust anti-obesity efficacy of PrRP31 analogues.
Why this rating
Preclinical animal study (DIO mice); not human clinical data.
Source
Lipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect
Flora Alexopoulou et al. · Scientific Reports · 2022
DOI 10.1038/s41598-022-05310-y
mechanism_only · n=56Cited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →